Switzerland· 55234003
Diamicron MR 30 mg, comprimés à libération modifiée
A gliclazide product, registered in Switzerland by Servier (Suisse) SA and dispensed under Swissmedic category B. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Gliclazide is registered in 14 of 19 countries.
Countries holding a registration under ATC A10BB09 (gliclazide), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Gliclazide · ATC A10BB09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of gliclazide costs, country by country.
Normalised to the WHO defined daily dose (60 mg), the median price runs from $0.11 in France to $0.61 in Switzerland — a ×5.5 gap.
- Switzerland: $0.61 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Gliclazide · price per daily dose (60 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.61
- IT Italy$0.26
- FR France$0.11
The record
At a glance
Swissmedic (Switzerland)- Manufacturer
- Servier (Suisse) SA
- Country
- Switzerland (CH)
- ATC code
- A10BB09
- ATC class
- Gliclazide
- Defined daily dose
- 60 mg, O
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- July 9, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
5 interactions on record for gliclazide.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gliclazide · interactions on record
5 records
5 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under A10BB09
Gliclazide, as other registers publish it.
- CanadaAG-GLICLAZIDE MRANGITA PHARMA INC.
- CanadaAG-GLICLAZIDE MRANGITA PHARMA INC.
- CanadaAPO-GLICLAZIDEAPOTEX INC
- CanadaAPO-GLICLAZIDE MRAPOTEX INC
- CanadaAPO-GLICLAZIDE MRAPOTEX INC
- United KingdomBilxona 30mg modified-release tabletsAccord-UK Ltd
- United KingdomBilxona 60mg modified-release tabletsActavis UK Ltd
- United KingdomBilxona 60mg modified-release tabletsAccord-UK Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d11d0a17-756e-4215-89a2-2000252b8c7a GET /v1/drugs/d11d0a17-756e-4215-89a2-2000252b8c7a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about gliclazide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.